Cigna Peers Weakened More, but the Stock Still Trails on Valuation Confidence

CI slipped 2.8% over the past week, a shade weaker than the median decline of around 2.3% for its closest managed-care peers. ELV fell 4.5% and CVS dropped 3.4%, so the sector selloff was broad, but UNH and CNC held up slightly better at 2.7% and 2.5% respectively.

Options positioning is the standout heading into Wednesday's print. The put/call ratio has eased further since the last preview, now at 0.42, about a standard deviation below its 20-day mean of 0.50. Call volume has dominated consistently for most of the past two weeks, with the ratio only briefly pushing above 0.53 on October 23. That one-sided lean is more pronounced than a week ago when the prior article flagged a ratio of 0.42 at 1.6 standard deviations below average; the z-score has since held near minus one, confirming the call-heavy tilt has not reversed. Short interest adds nothing bearish to the story: at 2.4% of free float, shares short are down a further 2.3% on the week, borrow availability is effectively unlimited, and cost to borrow at 0.26% is unremarkable for a stock of this size.

The analytic debate is sharper than the positioning implies. Cigna trades at roughly 9x trailing earnings and 7.2x EV/EBITDA, multiples that rank in the top decile of the peer group on earnings yield, yet the forward EPS momentum score sits at the 47th percentile, near the middle of the market. That tension captures the disagreement well. The bull case rests on Evernorth's specialty pharmacy platform, where more than one million complex-condition patients underpin 8%-to-12% annual growth, and on management's reaffirmed target of at least $30.45 in adjusted EPS for 2026. Bears counter that the long-term 10%-to-14% EPS CAGR commitment looks demanding: the company's own bridge assumes every business performs at the low end of its targets, five-year consolidated cash flow guidance has already been cut from roughly $60 billion to roughly $50 billion, and the Pharmacy Benefit Services growth range was trimmed to 0%-to-4%. Piper Sandler raised its target to $370 in early October, and the consensus mean sits at $342, implying roughly 15% upside from the current $298. But the mix of seven hold ratings against five outperform ratings reflects the Street's divided view on whether execution above the low end is achievable.

Past reactions offer a cautionary data point. The two most recent earnings events both produced immediate declines: the stock fell 2.7% on the day following the September print and dropped 5.9% the day after the July report. The five-day window after July extended the loss to 7.2%, though September recovered to a 1.2% gain over the same period. Wikipedia attention has also spiked, with a z-score of 2.2 against the stock's own 90-day history, a sign of elevated retail interest rather than any fundamental signal.

Thursday's print will test whether management's insistence on the $30.45 floor for 2026 EPS holds up alongside evidence of margin stability in the PBM transition, the question the call-heavy options market has implicitly priced as answerable.